Komori
General Meetings of Shareholders4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice of Convocation of the 2025 Annual General Meeting of Shareholders

For the 130th Annual General Meeting of Shareholders, the Company will submit proposals concerning the appropriation of surplus, the election of 8 directors nominated by the Company, and the election of 1 outside director nominated by a shareholder. The Board of Directors opposes the shareholder proposal.

Worth reading
75Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (130th)
2025年
6月24日
Date and time(火曜日)午前10時31 days from this disclosure to the meeting
Matters for resolution4 items (3 from the company, 1 from shareholders)
  1. Appropriation of surplus

  2. Election of 5 directors (excluding directors who are Audit and Supervisory Committee members)

  3. Election of 3 Directors who are Audit & Supervisory Committee Members

  4. 取締役(監査等委員である取締役を除く。)1名選任の件

    Shareholder Proposal
Shareholder Proposal

提案者は株主。第4号議案として松橋理氏を取締役に選任する提案。取締役会は反対。

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Director nominee会社提案8名(非監査等委員5名、監査等委員3名)。新任0名、社外2名。株主提案を含めると9名で、社外3名。
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (130th)
Date and time2025年6月24日(火曜日)午前10時
Matters for resolutionProposal 1: Appropriation of surplus, Proposal No. 2: Election of 5 directors (excluding directors who are Audit and Supervisory Committee members), Proposal 3: Election of 3 Directors who are Audit & Supervisory Committee Members, 第4号議案 取締役(監査等委員である取締役を除く。)1名選任の件
Shareholder Proposal提案者は株主。第4号議案として松橋理氏を取締役に選任する提案。取締役会は反対。
Director nominee会社提案8名(非監査等委員5名、監査等委員3名)。新任0名、社外2名。株主提案を含めると9名で、社外3名。
Items this document does not state (1)
Percentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

会社提案の取締役候補者については、経営体制の効率化を図るため非監査等委員取締役を6名から5名へ1名減員すると説明している。株主提案への反対理由として、会社提案の取締役会構成が必要なスキルの観点から最もバランスが取れており、中期経営計画の達成、経営執行の監督、企業価値の持続的向上に資するとしている。また、指名報酬委員会が株主提案候補者を選任する必要はないと判断したとしている。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of the 2025 Annual General Meeting of Shareholders | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori